[Multimodal therapy in locally advanced gastric cancer].
Locally advanced gastric cancers are characterized by poor prognosis. Clinical outcome can be improved if surgery becomes part of a multimodal treatment approach. The purpose of neoadjuvant treatment includes downsizing of the primary tumor, improvement of the T- and N- categories, and early therapy of micrometastasis. Several controlled clinical trials showed that neoadjuvant chemotherapy as well as neoadjuvant combined radio-chemotherapy, especially for tumors of the gastroesophageal junction, can improve the rate of primary R0 resections, relapse-free survival, and overall survival. While patients with locally advanced tumors clearly benefit from this strategy, the approach is still controversial in patients with early stage disease. Nonresponders do not benefit from neoadjuvant therapy. Therefore, response evaluation and response prediction are of great importance. After successful neoadjuvant chemotherapy, patients should undergo gastrectomy with D(2)-lymphadenectomy because of a high probability of lymph node metastasis. This article summarizes current developments in this field.
Klinik für Strahlentherapie und Radiologische Onkologie, Universitätsklinik Düsseldorf. boelke@med.uni-duesseldorf.de
E
E
Bölke
M
M
Peiper
W T
WT
Knoefel
S E
SE
Baldus
M
M
Schauer
C
C
Matuschek
P A
PA
Gerber
N-P
NP
Hoff
W
W
Budach
N
N
Gattermann
A
A
Erhardt
A
A
Scherer
B A
BA
Buhren
K
K
Orth
D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D008197:Lymph Node Excision; D020360:Neoadjuvant Therapy; D061206:Neoplasm Micrometastasis / Q000517:prevention & control / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D013274:Stomach Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D016896:Treatment Outcome